Carlsbad-Based A.I. Startup Enlists UCSD Health’s Kader to Chair Advisory Board
Published by Times of San Diego in Ai San Diego · Friday 08 Mar 2024
Tags: Times, of, San, Diego, Ai, San, Diego
Tags: Times, of, San, Diego, Ai, San, Diego
An AI startup that seeks to improve patient outcomes by rapidly discovering hidden patterns in life sciences data has named a UC San Diego Health physician and professor to its advisory board.
Dr. A. Karim Kader, a professor of urology, has joined Carlsbad-based Limmi’s advisory board as chairman.
In addition to Dr. Kader’s work at UCSD, he also spent 15 years building Stratify Genomics, a biotech company founded to commercialize genetic tests to determine a patient’s risk of developing prostate cancer.
Limmi, founded in 2022, utilizes cutting-edge artificial intelligence and deep learning methodologies on a platform built specifically for healthcare and biotech, offering customers real-time predictions and insights to patients.
The aim? “Radically changing the way their customers manage healthcare operations and patient health management,” according to a news release from Limmi.
“We’re in a desperate need at this time for solutions like the one Limmi is offering. We’re creating all this big data that we don’t know what to do with – because we’re only human and we can not process all of the different data points that we get as clinicians in a sensical fashion.” Kader said in the release.
He worked 15 years on his discovery regarding genetic risk in prostate cancer and establishing his company, an effort he thinks “I could have done in probably three to five years with Limmi’s technology – and brought this product to patients much sooner.”
In addition to being a board-certified urologist who specializes in detecting, treating and preventing prostate cancer, Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for genetic discoveries related to early detection of prostate cancer.
“We are very pleased to welcome Dr. Karim Kader to our board and we look forward to leveraging his talent, expertise and veteran leadership as a researcher, innovator and a practicing surgeon,” states Limmi’s co-founder and Chairman of the Board, Trevor Vieweg.